Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ligand Pharma (LGND) PT Raised to $237 at H.C. Wainwright
February 7, 2020 8:29 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Ligand Pharma (NASDAQ: LGND) to $237.00 (from $214.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced 4Q19 and 2019 financial results, posting GAAP EPS of ($0.43) and $33.13 per share, respectively, compared with our... More
Ligand Pharma (LGND) Tops Q4 EPS by 8c
February 6, 2020 4:05 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.71, $0.08 better than the analyst estimate of $0.63. Revenue for the quarter came in at $27 million versus the consensus estimate of $25.2 million.
Ligand made tremendous progress during 2019 in areas that will drive our future success, including new license agreements, outstanding revenue performance driven by record revenue for Captisol and Kyprolis royalties, expansion of our proprietary technology platforms and continued investment in internal programs, said John Higgins,... More
